Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics
- 14 June 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (12), 5004-5013
- https://doi.org/10.1158/0008-5472.can-10-0066
Abstract
Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-kappaB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-kappaB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-kappaB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO.Other Versions
This publication has 30 references indexed in Scilit:
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Sulforaphane targets pancreatic tumour-initiating cells by NF- B-induced antiapoptotic signallingGut, 2008
- VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinomaBritish Journal of Cancer, 2008
- Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancerCancer Gene Therapy, 2008
- Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic CancerCell Stem Cell, 2007
- Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancersJournal of Cellular and Molecular Medicine, 2007
- BAY 43-9006 Inhibition of Oncogenic RET MutantsJNCI Journal of the National Cancer Institute, 2006
- Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsAnnals of Oncology, 2006
- NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cellsInternational Journal of Cancer, 2003
- Critical Role of RelB Serine 368 for Dimerization and p100 StabilizationPublished by Elsevier BV ,2003